Platelet dysfunction in immune thrombocytopenia: Finding clinical subsets with platelet phenotypes
Authors:
- Sidra A. AliSASidra A. Ali
- Sarah M. HicksSHSarah M. Hicks
- Lucy A. CouplandLCLucy A. Coupland
- Simone A. BryslandSBSimone A. Brysland
- Vijay BhoopalanVBVijay Bhoopalan
- Yee Lin ThongYTYee Lin Thong
- Amandeep KaurAKAmandeep Kaur
- Robert K. AndrewsRARobert K. Andrews
- Elizabeth E. GardinerEGElizabeth E. Gardiner
- Philip Y.‐I. ChoiPCPhilip Y.‐I. Choi
Open Access
- 29 September 2025
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 208 (1) , 274-284
Abstract
Summary: Patients with immune thrombocytopenia (ITP) remain a challenge to diagnose, manage and predict bleeding risk. A comprehensive assessment of platelet function may aid clinical management. This study assessed platelet parameters to predict bleeding in ITP. Blood from 103 clinically annotated cases with isolated thrombocytopenia and 123 healthy donors was evaluated. In the ITP cohort, 75/110 encounters (68%) had platelet counts below 50 × 10 9 /L. Platelet surface proteins, reticulated platelets and activation were quantified using flow cytometry. Soluble receptor fragments, citrullinated histone‐DNA (CitH3‐DNA) complexes and thrombopoietin (TPO) were quantified by enzyme‐linked immunosorbent assay (ELISA). Whole blood clotting and platelet contribution to clot formation were evaluated using viscoelastography. Elevated levels of glycoprotein (GP) VI ( p = 0.0012), Trem‐like transcript‐1 (TLT‐1) ( p = 0.0248), platelet‐bound immunoglobulin (Ig) G ( p < 0.0029), CitH3‐DNA complexes ( p = 0.0022), TPO ( p < 0.0001) and reduced platelet contribution to clot formation ( p < 0.0001) were observed in primary ITP patients with bleeding and bruising symptoms. A multivariable analysis revealed that measuring platelet indices strengthened a predictive bleeding model over platelet count alone (78.1% vs. 70.48%). Symptomatic ITP patients have measurable platelet dysfunction and quantifiable differences on platelet surface, increased evidence of NETosis and elevated TPO levels. Identifying biomarkers for ITP outcomes can define subsets of disease with clinical relevance.Keywords
Funding Information
- National Health and Medical Research Council (APP2018835)
- National Health and Medical Research Council (APP2000485)
- ACT Health (RIF2022001)
- International Society on Thrombosis and Haemostasis (ISTH RTWF 2019)
- National Blood Authority (NBA IgSO1)
This publication has 46 references indexed in Scilit:
- Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 studyThe Lancet Haematology, 2023
- The role of platelets in immune-mediated inflammatory diseasesNature Reviews Immunology, 2023
- Platelet function and soluble P-selectin in patients with primary immune thrombocytopeniaThrombosis Research, 2023
- Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseasesNature Reviews Immunology, 2022
- Recent advances in the mechanisms and treatment of immune thrombocytopeniaEBioMedicine, 2022
- Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonistsThrombosis Research, 2020
- Pathophysiology of Autoimmune Thrombocytopenia: Current Insight with a Focus on ThrombopoiesisHamostaseologie, 2019
- Anti‐glycoprotein VI mediated immune thrombocytopenia: An under‐recognized and significant entity?Research and Practice in Thrombosis and Haemostasis, 2017
- Thrombopoietin levels in patients with disorders of platelet production: Diagnostic potential and utility in predicting response to TPO Receptor agonistsAmerican Journal of Hematology, 2013
- The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reportsAmerican Journal of Hematology, 2010